Friday, July 10, 2026

pharma · Diabetic Macular Edema · Hypercholesterolemia · REGN

Regeneron UK

Regeneron UK is a pharma organization headquartered in Tarrytown, USA. It trades on NYSE under ticker REGN. Primary therapeutic focus areas include Diabetic Macular Edema, Hypercholesterolemia, Asthma, Macular Degenerati

Tarrytown, USA HQ
16,715 Employees
Public company Type
REGN · NYSE Ticker
Company details
Clinical program

ALN-CIDEB

Phase 2 · small molecule · Metabolic Dysfunction-Associated Steatotic Liver Disease

ALN-CIDEB for Metabolic Dysfunction-Associated Steatotic Liver Disease is a Phase 2 program (small_molecule) at Regeneron UK Limited with 1 ClinicalTrials.gov record(s).

← All Regeneron UK Limited projects Phase 2 small molecule active

Internal code ALN-CIDEB-NASH-2486

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Regeneron UK Limited
Phase
Phase 2
Modality
small_molecule
Indication
Metabolic Dysfunction-Associated Steatotic Liver Disease
Status
active
Trials
1

Clinical trials